Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Bio-Rad likely is undervalued today, but I still don’t really like the business. I can appreciate the argument that this is a way to leverage a stake in Sartorius with operational execution upside at ...